NextSource Biotechnology Announces FDA Short Supply release of the formally known Bristol Myers Squibb (CeeNu®) Brand Oncology product now currently marketed under the NextSource Biotechnology Lomustine (CCNU) label Exclusively in the United States.

MIAMI, Jan. 24, 2014 -- NextSource BioTechnology, LLC, (NSB), an emerging Specialty Pharmaceutical Manufacturing and Marketing Company focused on Consolidating, Re-Branding and Launching "Matured & Orphan Drugs," has announced its most recent product Lomustine (CCNU)... Read more »

NextSource Biotechnology Launches New Strategic Approach to Mitigate Slow-Downs in Manufacturing of Matured Medications in High Demand. NextSource Biotechnology Re-Introduces Critical Oncology Medication avoiding major losses in the Healthcare Sector.

MIAMI, Sept. 23, 2013 -- NextSource Biotechnology, LLC., (NSB), a leading Specialty Pharmaceutical Manufacturing and Marketing company with a strategic objective of Consolidating, Re-Branding and launching a "Matured & Orphan Drugs" product portfolio in the U.S. and International Healthcare Markets. By utilizing a worldwide distribution network... Read more »

Counterfeit medicine is fake medicine. It may be contaminated or contain the wrong or no active ingredient. They could have the right active ingredient but at the wrong dose. Counterfeit drugs are illegal and may be harmful to your health. FDA takes all reports of suspect counterfeits seriously and, in order to combat counterfeit medicines, is working with other agencies and the private sector to help protect the nation’s drug supply from the threat of counterfeits.


U.S. Food and Drug Administration: Counterfeit Medicines
Partnership for Safe Medicines
Learn About Counterfeit Drugs Around the Globe
Buying Prescription Medicine Online: A Consumer Safety Guide
Supply Chain Security
Cargo Theft